Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaomeng Wang

Showing results (151-160 of 480) with videos related to

Pageof 48
Sort By:
Journal of Medicinal Chemistry|June 8, 2023
Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor ActivityJiantao Hu, Biao Hu, Fuming Xu, et al.
ACS Medicinal Chemistry Letters|July 3, 2010
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 InhibitorsJianyong Chen, Longchuan Bai, Denzil Bernard, et al.
Journal of Medicinal Chemistry|December 16, 2014
Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindolesAngelo Aguilar, Wei Sun, Liu Liu, et al.
Cancer Research|March 26, 2009
TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathwayZhiwei Wang, Asfar Sohail Azmi, Aamir Ahmad, et al.
Leukemia|April 15, 2026
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX modelsMalathi Kandarpa, Luke F Peterson, Harish Potu, et al.
Plos One|June 13, 2015
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug TreatmentC Gianna Hoffman-Luca, Chao-Yie Yang, Jianfeng Lu, et al.
Molecular Cancer Therapeutics|July 23, 2008
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repairMahmoud Toulany, Rainer Kehlbach, Urszula Florczak, et al.
Molecular Pharmaceutics|September 18, 2010
Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug releasePeng Zou, Yanke Yu, Y Andrew Wang, et al.
ACS Medicinal Chemistry Letters|October 18, 2023
Discovery of Pyrrolo[2,3-<i>c</i>]pyridines as Potent and Reversible LSD1 InhibitorsCanhui Zheng, Rohan Kalyan Rej, Mi Wang, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategyYipin Lu, Zaneta Nikolovska-Coleska, Xueliang Fang, et al.
Pageof 48

Showing results (151-160 of 480) with videos related to

Sort By:
Pageof 48
Journal of Medicinal Chemistry|June 8, 2023
Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor ActivityJiantao Hu, Biao Hu, Fuming Xu, et al.
ACS Medicinal Chemistry Letters|July 3, 2010
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 InhibitorsJianyong Chen, Longchuan Bai, Denzil Bernard, et al.
Journal of Medicinal Chemistry|December 16, 2014
Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindolesAngelo Aguilar, Wei Sun, Liu Liu, et al.
Cancer Research|March 26, 2009
TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathwayZhiwei Wang, Asfar Sohail Azmi, Aamir Ahmad, et al.
Leukemia|April 15, 2026
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX modelsMalathi Kandarpa, Luke F Peterson, Harish Potu, et al.
Plos One|June 13, 2015
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug TreatmentC Gianna Hoffman-Luca, Chao-Yie Yang, Jianfeng Lu, et al.
Molecular Cancer Therapeutics|July 23, 2008
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repairMahmoud Toulany, Rainer Kehlbach, Urszula Florczak, et al.
Molecular Pharmaceutics|September 18, 2010
Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug releasePeng Zou, Yanke Yu, Y Andrew Wang, et al.
ACS Medicinal Chemistry Letters|October 18, 2023
Discovery of Pyrrolo[2,3-<i>c</i>]pyridines as Potent and Reversible LSD1 InhibitorsCanhui Zheng, Rohan Kalyan Rej, Mi Wang, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategyYipin Lu, Zaneta Nikolovska-Coleska, Xueliang Fang, et al.
Pageof 48